Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) reported a share buy-back on 17 June 2026, acquiring 308,400 H shares on the Hong Kong Stock Exchange.

• Transaction details – Purchase method: On-market repurchase – Price range: HKD 3.18–3.22 per share – Volume-weighted average price: HKD 3.2014 per share – Total consideration: HKD 0.99 million

• Impact on share capital – Outstanding shares (excluding treasury) decreased from 4,463.53 million to 4,463.22 million. – Treasury shares increased from 58.81 million to 59.11 million. – The reduction represents 0.0069% of the company’s issued share capital (excluding treasury shares) prior to the transaction. – Total issued shares remained unchanged at 4,522.33 million.

• Mandate utilisation – Shareholders authorised up to 446.46 million shares for repurchase on 29 May 2026. – Cumulative buy-backs under this mandate now stand at 1.79 million shares, equivalent to 0.40% of the shares outstanding on the mandate date. – In line with Hong Kong listing rules, WEIGAO GROUP is subject to a moratorium on new share issues or treasury-share sales until 17 July 2026.

The company confirmed that all repurchases were executed in compliance with the Hong Kong Stock Exchange’s Main Board Rules and other applicable regulations.